Thursday, April 9, 2026

Zentalis selects 400mg once-daily 5:2 azenosertib monotherapy pivotal dose for ovarian cancer trials

 

Zentalis selects 400mg once-daily 5:2 azenosertib monotherapy as pivotal dose for DENALI and ASPENOVA ovarian cancer trials

  • DENALI is a Phase 2 trial and ASPENOVA a Phase 3 trial in ovarian cancer
  • Both trials are in Cyclin E1-positive platinum-resistant ovarian cancer
  • Dose selection was based on interim DENALI Part 2a data
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.